Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evommune, Inc. Common Stock (NY:EVMN)

20.69 +0.96 (+4.87%)
Official Closing Price Updated: 7:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 440,296
Open 19.66
Bid (Size) 19.80 (100)
Ask (Size) 22.00 (100)
Prev. Close 19.73
Today's Range 19.63 - 21.11
52wk Range 13.88 - 33.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+19.5%
+19.5%
1 Month
-12.4%
-12.4%
3 Month
-12.3%
-12.3%
6 Month
-2.5%
-2.5%
1 Year
+2.3%
+2.3%

More News

Read More
News headline image
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? ↗
Via Stocktwits
News headline image
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
From Evommune, Inc.
Via Business Wire
News headline image
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade ↗
Via The Motley Fool
News headline image
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
From Evommune, Inc.
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Evommune Announces $125 Million Private Placement
From Evommune, Inc.
Via Business Wire
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
From Evommune, Inc.
Via Business Wire
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
Via MarketBeat
News headline image
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
From Evommune, Inc.
Via Business Wire

Frequently Asked Questions

Is Evommune, Inc. Common Stock publicly traded?
Yes, Evommune, Inc. Common Stock is publicly traded.
What exchange does Evommune, Inc. Common Stock trade on?
Evommune, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Evommune, Inc. Common Stock?
The ticker symbol for Evommune, Inc. Common Stock is EVMN on the New York Stock Exchange
What is the current price of Evommune, Inc. Common Stock?
The current price of Evommune, Inc. Common Stock is 20.69
When was Evommune, Inc. Common Stock last traded?
The last trade of Evommune, Inc. Common Stock was at 06/04/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.